Serif provides a programmable nucleic acid platform that lets researchers embed therapeutic functions directly into the genome, enabling precise, durable control of DNA and RNA activity in vivo. The technology supports rapid development of custom gene and RNA medicines for pharmaceutical and biotech companies, with built‑in safety controls to reduce off‑target effects.
Funding
Funding not disclosed
Founders
Product
Problem
Current genetic medicine approaches are limited in their ability to precisely control DNA and RNA behavior within living organisms, restricting the development of durable and targeted gene-based therapies.
Solution
Serif creates programmable nucleic acid platforms that allow researchers to encode therapeutic functions directly into the genome. By engineering nucleic acids to behave in predefined ways in vivo, the technology enables the design of genetic medicines with higher specificity and lasting effect. This platform supports both treatment and prevention strategies across a range of diseases, offering a new class of interventions that go beyond conventional gene editing or RNA therapeutics. The approach leverages advanced molecular programming to translate genomic sequences into functional medicines.
Target Audience
Primary customers are pharmaceutical and biotechnology companies developing next‑generation gene and RNA therapies, as well as research institutions focused on genetic medicine innovation.
Features
- Programmable nucleic acid constructs that can be tailored to modulate DNA and RNA activity in vivo
- Ability to embed therapeutic functions directly within the genome for durable effects
- Platform-agnostic design supporting multiple disease targets and therapeutic modalities
- Scalable synthesis and validation pipeline for rapid development of custom genetic medicines
- Integrated safety controls to minimize off‑target activity and ensure precise gene regulation